Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $68.19 and last traded at $64.50, with a volume of 392739 shares trading hands. The stock had previously closed at $64.96.
Gemini Therapeutics Trading Up 3.0 %
The company has a market cap of $2.80 billion, a P/E ratio of -62.65 and a beta of -0.12. The firm’s 50 day moving average price is $52.78 and its 200-day moving average price is $46.58.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Read More
- Five stocks we like better than Gemini Therapeutics
- The How and Why of Investing in Gold Stocks
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- What Are Dividend Achievers? An Introduction
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
